Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

MLYS

Mineralys Therapeutics Inc

Dec 12 • 04:00PM ET

12.17

Dollar change -0.78
Percentage change -6.02	%

Healthcare • Biotechnology • USA • NASD

Peers: FENC AKBA EOLS ARDX ESPR PDSB KNSA ACXP CRVS ATHE

| Held by: IWM VTI VXF IWN IBB VTWO HRTS SCHA IWC IWO

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-3.27	Insider Own	52.67%	Shs Outstand	49.76M	Perf Week	-0.41%
Market Cap	605.68M	Forward P/E	-	EPS next Y	-3.85	Insider Trans	-3.15%	Shs Float	23.55M	Perf Month	-9.04%
Income	-153.25M	PEG	-	EPS next Q	-1.08	Inst Own	49.46%	Short Float	6.00%	Perf Quarter	3.49%
Sales	0.00M	P/S	-	EPS this Y	-85.50%	Inst Trans	0.81%	Short Ratio	8.01	Perf Half Y	-4.10%
Book/sh	4.76	P/B	2.56	EPS next Y	-4.21%	ROA	-56.16%	Short Interest	1.41M	Perf Year	71.65%
Cash/sh	5.30	P/C	2.30	EPS next 5Y	-	ROE	-61.19%	52W Range	6.99 - 16.91	Perf YTD	41.51%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-64.68%	52W High	-28.01%	Beta	1.57
Dividend TTM	-	Quick Ratio	8.55	Sales past 5Y	0.00%	Gross Margin	-	52W Low	74.11%	ATR (14)	0.86
Dividend Ex-Date	-	Current Ratio	8.55	EPS Y/Y TTM	-136.84%	Oper. Margin	-	RSI (14)	44.02	Volatility	7.45% 7.24%
Employees	28	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	32.57
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	-104.26%	Payout	-	Rel Volume	0.62	Prev Close	12.95
Sales Surprise	-	EPS Surprise	-30.89%	Sales Q/Q	-	Earnings	Nov 11 AMC	Avg Volume	176.36K	Price	12.17
SMA20	-3.37%	SMA50	-8.38%	SMA200	-4.20%	Trades		Volume	108,240	Change	-6.02%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-10-24	Initiated	H.C. Wainwright	Buy	$30
Apr-02-24	Initiated	Goldman	Buy	$30
Mar-07-23	Initiated	Wells Fargo	Overweight	$27
Mar-07-23	Initiated	Stifel	Buy	$45
Mar-07-23	Initiated	Guggenheim	Buy	$32
Mar-07-23	Initiated	Evercore ISI	Outperform
Mar-07-23	Initiated	Credit Suisse	Outperform	$40
Mar-07-23	Initiated	BofA Securities	Buy	$39

Nov-12-24 11:00PM	Mineralys Therapeutics Announces Q3 2024 Results and Updates (TipRanks) -10.32% -6.95%
10:12AM	Q3 2024 Mineralys Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-11-24 04:05PM	Mineralys Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire) +6.27%
Nov-05-24 04:05PM	Mineralys Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire) +10.66%
Nov-04-24 04:05PM	Mineralys Therapeutics to Announce Third Quarter 2024 Financial Results and Host Conference Call on Monday, November 11, 2024 (GlobeNewswire)
08:00AM	Loading…
Oct-30-24 08:00AM	Mineralys Therapeutics Completes Enrollment Ahead of Schedule in Launch-HTN, the Second Pivotal Trial of Lorundrostat for the Treatment of Hypertension (GlobeNewswire)
Oct-22-24 08:00AM	Mineralys to Host Virtual KOL Event on the Unmet Medical Need in Uncontrolled and Resistant Hypertension, and Lorundrostat as a Potential Treatment on October 30, 2024 (GlobeNewswire)
Sep-25-24 08:00AM	Mineralys Therapeutics Completes Target Enrollment in Pivotal Advance-HTN Trial of Lorundrostat for the Treatment of Hypertension (GlobeNewswire)
Aug-28-24 08:00AM	Mineralys Therapeutics to Participate in the Wells Fargo Healthcare Conference (GlobeNewswire)
Aug-13-24 04:05PM	Mineralys Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire) -22.82%
Aug-05-24 04:05PM	Mineralys Therapeutics to Announce Second Quarter 2024 Financial Results and Host Conference Call on Tuesday, August 13, 2024 (GlobeNewswire) -5.66%
Jul-12-24 07:01PM	Mineralys Therapeutics Inc (MLYS) CEO Jon Congleton Sells 15,746 Shares (GuruFocus.com) +6.71%
07:01PM	Insider Sale at Mineralys Therapeutics Inc (MLYS): CFO and Secretary Adam Levy Sells Shares (GuruFocus.com)
Jun-21-24 03:11AM	Insider Sale: CEO Jon Congleton Sells Shares of Mineralys Therapeutics Inc (MLYS) (GuruFocus.com)
Jun-15-24 02:53AM	Mineralys Therapeutics Inc (MLYS) CEO Jon Congleton Sells 72,797 Shares (GuruFocus.com)
08:00AM	Loading…
Jun-14-24 08:00AM	Mineralys Therapeutics Appoints Biopharmaceutical Executive Alexander M. Gold, M.D. to its Board of Directors (GlobeNewswire)
02:43AM	Insider Sale: CFO and Secretary Adam Levy Sells 96,815 Shares of Mineralys Therapeutics Inc (MLYS) (GuruFocus.com)
Jun-03-24 08:00AM	Mineralys Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference (GlobeNewswire)
May-13-24 11:45AM	Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-09-24 11:56AM	MLYS Stock Earnings: Mineralys Therapeutics Misses EPS for Q1 2024 (InvestorPlace)
07:00AM	Mineralys Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
May-06-24 08:00AM	Mineralys Therapeutics to Participate in the Bank of America Securities Health Care Conference (GlobeNewswire) +6.18%
May-02-24 08:00AM	Mineralys Therapeutics to Announce First Quarter 2024 Financial Results and Host Conference Call on Thursday, May 9, 2024 (GlobeNewswire)
Apr-05-24 12:16AM	Goldman Sachs Predicts Over 120% Rally for These 2 Strong Buy Stocks (TipRanks)
Mar-22-24 10:51AM	Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-21-24 11:53AM	MLYS Stock Earnings: Mineralys Therapeutics Beats EPS for Q4 2023 (InvestorPlace)
09:11AM	Mineralys Therapeutics Inc (MLYS) Reports Increased R&D Expenses Amid Progress in ... (GuruFocus.com)
07:00AM	Mineralys Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-13-24 04:05PM	Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on Thursday, March 21, 2024 (GlobeNewswire)
Feb-08-24 08:00AM	Mineralys Therapeutics Announces $120 Million Private Placement Financing (GlobeNewswire) +12.51%
04:05PM	Loading…
Jan-29-24 04:05PM	Mineralys Therapeutics to Participate in the Guggenheim Securities 6th Annual Biotechnology Conference (GlobeNewswire) +6.21%
Jan-17-24 12:00PM	Mineralys Therapeutics, Inc. (MLYS) Upgraded to Strong Buy: Here's What You Should Know (Zacks)
Jan-04-24 04:05PM	Mineralys Therapeutics Appoints Minji Kim, Ph.D. as Chief Business Officer (GlobeNewswire)
Dec-21-23 04:05PM	Mineralys Therapeutics Announces First Subject Dosed in Launch-HTN, the Second Pivotal Trial of Lorundrostat for the Treatment of Hypertension (GlobeNewswire) +8.30%
Nov-12-23 09:22AM	Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-11-23 11:30AM	Mineralys Therapeutics Further Defines Endotype-Specific, Targeted Approach to Treatment of Uncontrolled or Resistant Hypertension with Lorundrostat Data at AHA Scientific Sessions 2023 (GlobeNewswire)
Nov-09-23 04:05PM	Mineralys Therapeutics to Participate in Three Upcoming Conferences (GlobeNewswire) -9.31% -12.84%
Nov-07-23 05:12PM	Mineralys Therapeutics Inc (MLYS) Reports Q3 2023 Financials; R&D Expenses Rise Amid ... (GuruFocus.com) +8.02% -6.74%
04:05PM	Mineralys Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-02-23 10:00AM	Mineralys Therapeutics Presents New Post-Hoc Analysis from Target-HTN Phase 2 Trial of Lorundrostat in Late-Breaking Poster Session at ASN Kidney Week 2023 Meeting (GlobeNewswire)
Oct-31-23 04:05PM	Mineralys Therapeutics to Announce Third Quarter 2023 Financial Results and Host Conference Call on Tuesday, November 7, 2023 (GlobeNewswire)
Oct-13-23 04:10PM	Mineralys Therapeutics Announces Upcoming Poster Presentations at Two Scientific Conferences in November 2023 (GlobeNewswire) +5.59% +5.19%
Sep-19-23 04:00PM	Praxis Bioresearch Expands its Board of Directors with Appointment of Adam Levy (GlobeNewswire)
Sep-14-23 04:05PM	Mineralys Therapeutics Expands its Board of Directors with Appointments of Glenn Sblendorio and Daphne Karydas (GlobeNewswire)
Sep-11-23 04:05PM	Mineralys Therapeutics to Participate in the Cantor Fitzgerald Global Healthcare Conference on Thursday, September 28, 2023 (GlobeNewswire)
Sep-10-23 07:47AM	Mineralys Therapeutics Announces JAMA Publication of Full Target-HTN Phase 2 Trial Results for Lorundrostat in Uncontrolled and Treatment-Resistant Hypertension (GlobeNewswire)
07:45AM	Mineralys Therapeutics Presents Target-HTN Phase 2 Trial Results in Late-Breaking Science Session at 2023 AHA Hypertension Scientific Sessions (GlobeNewswire)
Sep-09-23 05:00AM	CEO Jon Congleton Buys 2,250 Shares of Mineralys Therapeutics Inc (MLYS) (GuruFocus.com)
Sep-05-23 04:05PM	Mineralys Therapeutics Selected for Oral Poster Presentation of Target-HTN Phase 2 Trial Results at 2023 AHA Hypertension Scientific Sessions (GlobeNewswire) -5.57%
09:55AM	Wall Street Analysts See a 199.3% Upside in Mineralys Therapeutics, Inc. (MLYS): Can the Stock Really Move This High? (Zacks)
Aug-29-23 04:05PM	Mineralys Therapeutics to Participate in the Wells Fargo Securities Healthcare Conference on Thursday, September 7, 2023 (GlobeNewswire)
Aug-22-23 05:45PM	Mineralys Therapeutics, Inc. (MLYS) Loses -19.64% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks) +8.84%
Aug-07-23 04:05PM	Mineralys Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire) -6.02% +6.96%
Jul-31-23 04:05PM	Mineralys Therapeutics to Announce Second Quarter 2023 Financial Results and Host Conference Call on Monday, August 7, 2023 (GlobeNewswire)
Jul-17-23 04:01PM	Mineralys Therapeutics Announces Expansion of Planned Phase 2 Trial of Lorundrostat Alone and in Combination with SGLT2 Inhibitor to Treat Patients with Chronic Kidney Disease (CKD) (GlobeNewswire)
Jun-09-23 08:04AM	10 Struggling IPOs To Buy For The Long-Term (Insider Monkey)
May-31-23 08:00AM	Mineralys Therapeutics to Participate in the Jefferies Healthcare Conference (GlobeNewswire)
May-15-23 04:01PM	Mineralys Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
May-10-23 08:39AM	We Think Mineralys Therapeutics (NASDAQ:MLYS) Can Afford To Drive Business Growth (Simply Wall St.)
May-02-23 08:00AM	Mineralys Therapeutics Announces First Patient Dosed in the ADVANCE-HTN Pivotal Trial of Lorundrostat for the Treatment of Uncontrolled and Resistant Hypertension (GlobeNewswire)
May-01-23 08:00AM	Mineralys Therapeutics to Announce First Quarter 2023 Financial Results and Host Conference Call on Monday, May 15, 2023 (GlobeNewswire)
Apr-27-23 04:47PM	Mineralys Therapeutics to Participate in the Bank of America Securities 2023 Health Care Conference on Wednesday, May 10, 2023 (GlobeNewswire)
Mar-15-23 04:01PM	Mineralys Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update (GlobeNewswire) -5.93%
Mar-04-23 04:30PM	Mineralys Therapeutics Presents Positive Lorundrostat Results from the Phase 2 Target-HTN Trial at ACC.23/WCC (GlobeNewswire)
Mar-01-23 04:05PM	Mineralys Therapeutics to Announce Fourth Quarter 2022 Financial Results and Host Conference Call on Wednesday, March 15, 2023 (GlobeNewswire)
Feb-20-23 08:00AM	Mineralys Therapeutics Abstracts Selected to be Presented at the American College of Cardiology Annual Scientific Session & Expo Together with the World Congress of Cardiology (ACC.23/WCC) in March 2023 (GlobeNewswire)
Feb-17-23 12:08PM	Lab Notes: AnPac dips into real estate with diversification strategy; Mineralys closes $220.8M IPO (American City Business Journals)
Feb-14-23 04:01PM	Mineralys Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares (GlobeNewswire)
Feb-10-23 05:16PM	Mineralys, Enlight Trading Debuts Add to Big Week for US IPOs (Bloomberg)

Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing medicines to target diseases driven by abnormally elevated aldosterone. Its clinical-stage product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that are initially developing for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone, including hypertension and chronic kidney disease. The company was founded by Brian Taylor Slingsby on May 31, 2019 and is headquartered in Radnor, PA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Rodman David Malcom	Chief Medical Officer	Nov 11 '24	Option Exercise	0.81	10,043	8,137	146,017	Nov 12 05:25 PM
Rodman David Malcom	Chief Medical Officer	Nov 11 '24	Sale	15.00	5,026	75,398	140,991	Nov 12 05:25 PM
Rodman David Malcom	Officer	Nov 11 '24	Proposed Sale	15.00	5,026	75,398		Nov 12 10:40 AM
Rodman David Malcom	Chief Medical Officer	Nov 06 '24	Option Exercise	1.08	25,482	27,521	161,456	Nov 08 04:21 PM
Rodman David Malcom	Chief Medical Officer	Nov 06 '24	Sale	15.03	25,482	383,066	135,974	Nov 08 04:21 PM
Rodman David Malcom	Officer	Nov 06 '24	Proposed Sale	15.03	25,482	383,067		Nov 06 06:43 PM
Levy Adam Scott	CFO and Secretary	Oct 11 '24	Sale	13.57	10,757	146,004	236,854	Oct 15 04:22 PM
Rodman David Malcom	Chief Medical Officer	Oct 14 '24	Option Exercise	1.08	5,352	5,780	135,974	Oct 15 04:22 PM
Rodman David Malcom	Chief Medical Officer	Oct 11 '24	Option Exercise	0.54	5,017	2,709	130,622	Oct 15 04:22 PM
Congleton Jon	Chief Executive Officer	Oct 11 '24	Sale	13.52	15,271	206,433	895,941	Oct 15 04:21 PM
Congleton Jon	Officer	Oct 11 '24	Proposed Sale	13.52	15,271	206,434		Oct 11 04:54 PM
Levy Adam Scott	Officer	Oct 11 '24	Proposed Sale	13.57	10,757	146,004		Oct 11 04:48 PM
Rodman David Malcom	Chief Medical Officer	Sep 12 '24	Option Exercise	1.08	6,349	6,857	125,605	Sep 12 04:32 PM
Rodman David Malcom	Chief Medical Officer	Sep 11 '24	Option Exercise	0.54	5,018	2,710	119,256	Sep 12 04:32 PM
Rodman David Malcom	Chief Medical Officer	Aug 12 '24	Option Exercise	0.84	11,365	9,565	114,238	Aug 13 04:20 PM
Slingsby Brian Taylor	Director	Jul 24 '24	Sale	13.05	550,000	7,177,500	8,644,579	Jul 26 09:45 PM
Rodman David Malcom	Chief Medical Officer	Jul 16 '24	Option Exercise	1.08	525	567	103,398	Jul 18 06:34 PM
Rodman David Malcom	Chief Medical Officer	Jul 16 '24	Sale	15.00	525	7,876	102,873	Jul 18 06:34 PM
Rodman David Malcom	Chief Medical Officer	Jul 12 '24	Option Exercise	1.08	6,349	6,857	102,873	Jul 12 04:39 PM
Rodman David Malcom	Chief Medical Officer	Jul 11 '24	Option Exercise	0.54	5,017	2,709	96,524	Jul 12 04:39 PM
Levy Adam Scott	CFO and Secretary	Jul 11 '24	Sale	13.14	10,757	141,394	247,611	Jul 12 04:37 PM
Congleton Jon	Chief Executive Officer	Jul 11 '24	Sale	13.34	15,746	210,075	911,212	Jul 12 04:36 PM
Congleton Jon	Chief Executive Officer	Jun 17 '24	Sale	12.25	17,766	217,712	958,505	Jun 20 05:44 PM
Congleton Jon	Chief Executive Officer	Jun 18 '24	Sale	11.99	16,607	199,073	941,898	Jun 20 05:44 PM
Congleton Jon	Chief Executive Officer	Jun 20 '24	Sale	11.73	14,940	175,237	926,958	Jun 20 05:44 PM
Congleton Jon	Chief Executive Officer	Jun 13 '24	Sale	12.74	39,961	509,027	992,500	Jun 14 06:15 PM
Congleton Jon	Chief Executive Officer	Jun 12 '24	Sale	12.77	16,607	212,013	1,032,461	Jun 14 06:15 PM
Congleton Jon	Chief Executive Officer	Jun 14 '24	Sale	12.52	16,229	203,163	976,271	Jun 14 06:15 PM
Levy Adam Scott	CFO and Secretary	Jun 11 '24	Sale	12.94	96,815	1,252,718	255,462	Jun 13 05:33 PM
Rodman David Malcom	Chief Medical Officer	Jun 12 '24	Option Exercise	1.08	6,349	6,857	89,729	Jun 13 05:32 PM
Rodman David Malcom	Chief Medical Officer	Jun 11 '24	Option Exercise	0.54	5,017	2,709	83,380	Jun 13 05:32 PM
Rodman David Malcom	Chief Medical Officer	May 13 '24	Option Exercise	0.84	11,366	9,566	78,363	May 15 04:43 PM
Rodman David Malcom	Chief Medical Officer	May 09 '24	Option Exercise	1.08	100	108	67,097	May 10 04:17 PM
Rodman David Malcom	Chief Medical Officer	May 09 '24	Sale	15.00	100	1,500	66,997	May 10 04:17 PM
Rodman David Malcom	Chief Medical Officer	Apr 12 '24	Option Exercise	1.08	6,349	6,857	66,997	Apr 15 04:24 PM
Rodman David Malcom	Chief Medical Officer	Apr 11 '24	Option Exercise	0.54	5,017	2,709	60,648	Apr 15 04:24 PM
Rodman David Malcom	Chief Medical Officer	Mar 12 '24	Option Exercise	1.08	6,348	6,856	55,631	Mar 13 05:35 PM
Rodman David Malcom	Chief Medical Officer	Mar 11 '24	Option Exercise	0.54	5,017	2,709	49,283	Mar 13 05:35 PM
Samsara BioCapital GP, LLC	10% Owner	Feb 12 '24	Buy	13.50	555,555	7,499,992	5,074,916	Feb 14 09:06 PM
Rodman David Malcom	Chief Medical Officer	Feb 12 '24	Option Exercise	0.84	11,366	9,566	44,266	Feb 13 04:08 PM
Rodman David Malcom	Chief Medical Officer	Jan 12 '24	Option Exercise	1.08	6,348	6,856	32,900	Jan 12 04:01 PM
Rodman David Malcom	Chief Medical Officer	Jan 11 '24	Option Exercise	0.54	5,017	2,709	26,552	Jan 12 04:01 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

MLYS

Mineralys Therapeutics Inc

Upgrade your FINVIZ experience